An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, will have its CEO Bassil Dahiyat present at the 41st Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 11, 2023, at 3:45 p.m. PST. A live webcast will be accessible in the Investors section of Xencor's website, with a replay available for 30 days post-event. Xencor focuses on developing engineered antibodies and cytokines to treat cancer and autoimmune diseases, with over 20 clinical candidates and three marketed medicines through partnerships.
Positive
None.
Negative
None.
MONROVIA, Calif.--(BUSINESS WIRE)--
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023 at 3:45 p.m. PST.
A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website. A replay will be available for at least 30 days following the presentation.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
